Anti-human L1CAM protein antibody 4D3
By providing specific anti-human L1CAM protein antibodies, the problem of neuron-derived exosome recognition and capture is solved, and the potential application of neurodegenerative disease diagnosis and tumor treatment is achieved, and the research and treatment understanding of neurological diseases is improved.
Patent Information
- Application Number
- CN202411216918.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-02
AI Technical Summary
The prior art is difficult to effectively identify and isolate exosomes from neuron origin, and the application of exosomes in the diagnosis of neurodegenerative diseases and tumor treatment is limited.
Provide an antibody or antigen-binding fragment thereof that contains specific light and heavy chain variable region amino acid sequences for specific recognition and capture of neuron-derived exosomes, prepared in combination with genetic engineering techniques and Detection method.
The specific identification and capture of neuron-derived exosomes is achieved, providing samples for diagnosis of neurodegenerative diseases and potential anti-cancer therapeutic targets, and enhancing the understanding of research and treatment of neurological disease biomarkers.
Smart Images

Figure CN118725118B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to an antibody against human L1CAM protein and relates to the field of immunotechnology. Background Art
[0002] L1CAM protein, or L1 cell adhesion molecule (L1CAM), is a neural adhesion protein in the immunoglobulin superfamily, existing in the form of membrane protein and free protein. Human L1CAM protein is a 200-220 kDa transmembrane glycoprotein in the immunoglobulin (Ig) superfamily, consisting of 6 Ig-like domains and 5 fibronectin type III repeats, followed by a transmembrane region and a highly conserved cytoplasmic tail region. L1CAM is widely present in the central nervous system (CNS), plays an important role in the development of the nervous system, and is an adhesion molecule involved in axon growth, bundling, neuronal migration and differentiation. L1CAM antibodies can specifically recognize exosomes derived from neurons and can be used as a key raw material for the specific capture of neuronal exosomes. The captured neuronal exosomes can be used as samples for the diagnosis of neurodegenerative diseases.
[0003] In addition, L1CAM, as a neural adhesion molecule, can regulate the growth and migration of tumor cells. A large number of studies have shown that L1CAM molecules are essential for many types of cancer cells to successfully metastasize to other normal organs. Normally, normal healthy tissues do not produce L1CAM, but advanced cancers are often accompanied by the production of L1CAM. L1CAM inhibitors can block the proliferation and migration of tumor cells in vitro and increase the chemotherapy sensitivity of tumor cells. Related data show that the use of L1CAM antibodies to treat mice with tumors can inhibit the spread of tumors. Therefore, L1CAM is of great significance in tumor formation and as a target for anti-cancer therapy.
[0004] Intercellular communication of exosomes in the CNS is also crucial for brain growth, development, and maintenance of homeostasis, and is associated with the occurrence and development of neurodegenerative diseases. Most of the previous studies on biomarkers of neurological diseases were based on peripheral tissues, and whether changes in the periphery can reflect changes in the CNS is the main limitation of the research, but the progress of exosome research has broken this dilemma. Previous studies on the content of exosomes in peripheral tissues, cerebrospinal fluid, and plasma may reflect ongoing neurological processes. Due to the overlap of extracellular vesicles in size, composition, and biomarkers, the separation and purification of exosomes remains a challenge. The development of techniques for accurately separating these extracellular vesicle subtypes will help to better understand the unique properties of exosomes in neural cell communication. Therefore, the purpose of the present invention is to provide an antibody to the L1CAM protein that can specifically recognize neuron-derived exosomes (NDE). Summary of the invention
[0005] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide an antibody or an antigenic fragment thereof against human L1CAM protein.
[0006] In order to achieve the above object, the present invention adopts the following technical solution:
[0007] The first aspect of the present invention provides an antibody or an antigen-binding fragment thereof against human L1CAM protein.
[0008] The antibody comprises LCDR1-LCDR3 of the light chain variable region as shown in SEQ ID NO: 1; and
[0009] The antibody comprises HCDR1-HCDR3 of the heavy chain variable region as shown in SEQ ID NO:2.
[0010] Furthermore, the LCDR of the light chain variable region and the HCDR of the heavy chain variable region may be numbered according to IMGT, Chothia, or Kabat.
[0011] The amino acid sequences of LCDR1-LCDR3 of the light chain variable region are shown in SEQ ID NOs:5-7; the amino acid sequences of HCDR1-HCDR3 of the heavy chain variable region are shown in SEQ ID NOs:8-10, wherein the CDR numbering is according to the IMGT numbering scheme.
[0012] The antibodies include monoclonal antibodies, polyclonal antibodies, humanized antibodies, chimeric antibodies or bivalent antibodies.
[0013] The second aspect of the present invention provides a nucleic acid molecule, a vector comprising the nucleic acid molecule, or a recombinant host cell comprising the nucleic acid molecule or the vector, wherein the nucleic acid molecule comprises a protein encoding the antibody or antigen-binding fragment thereof according to the first aspect of the present invention.
[0014] The nucleic acid molecule comprises LCDR1-LCDR3 of the light chain variable region base sequence as shown in SEQ ID NO: 3; and
[0015] The nucleic acid molecule comprises HCDR1-HCDR3 of the heavy chain variable region base sequence as shown in SEQ ID NO:4.
[0016] The base sequences of LCDR1-LCDR3 of the light chain variable region are shown in SEQ ID NOs: 11-13.
[0017] The base sequences of HCDR1-HCDR3 of the heavy chain variable region are shown in SEQ ID NOs: 14-16.
[0018] The third aspect of the present invention provides an antibody derivative, which comprises the antibody or antigenic fragment thereof according to the first aspect of the present invention and a detectable marker coupled thereto.
[0019] The detectable label comprises at least one of a radioisotope, a metal nanomaterial, a fluorescein, a biotin, avidin, a biotin / avidin protein complex, a biotin / avidin protein complex, a chromophore, an electron-dense substance, and an enzyme.
[0020] The fourth aspect of the present invention provides a method for preparing the antibody or antigen fragment thereof according to the first aspect of the present invention, wherein the method comprises artificial synthesis or preparation by genetic engineering technology.
[0021] The preparation using genetic engineering technology refers to culturing the recombinant host cell described in the second aspect of the present invention under conditions suitable for expressing antibodies.
[0022] The fifth aspect of the present invention provides a method for detecting human L1CAM protein, detecting or capturing neuronal exosomes, the method comprising using the antibody or antigenic fragment thereof described in the first aspect of the present invention and / or the antibody derivative described in the third aspect of the present invention to detect human L1CAM protein, and, detecting or capturing neuronal exosomes.
[0023] The sixth aspect of the present invention provides the use of the antibody or antigen-binding fragment thereof described in the first aspect of the present invention, the nucleic acid molecule described in the second aspect of the present invention and / or the antibody derivative described in the third aspect of the present invention in preparing a product.
[0024] The application includes any of the following:
[0025] 1) Application in the preparation of products for detecting human L1CAM protein;
[0026] 2) Application in the preparation of products for detecting or capturing neuronal exosomes;
[0027] 3) Application in the preparation of products for diagnosing neurodegenerative diseases.
[0028] Furthermore, the neurodegenerative diseases include Alzheimer's disease, Parkinson's syndrome, Huntington's disease, multiple sclerosis, primary lateral sclerosis, amyotrophic lateral sclerosis, and myasthenia gravis.
[0029] Another aspect of the present invention provides a method or pharmaceutical composition for treating a neurodegenerative disease, the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described in the first aspect of the present invention, the nucleic acid molecule described in the second aspect of the present invention and / or the antibody derivative described in the third aspect of the present invention and a pharmaceutically acceptable carrier.
[0030] Advantages and beneficial effects of the present invention:
[0031] The present invention provides an L1CAM protein antibody and an antigen-binding fragment thereof that can specifically recognize neuronal exosomes, which can be used as a key raw material for the specific capture of neuronal exosomes. The captured neuronal exosomes can be used as samples for the diagnosis of neurodegenerative diseases, providing important materials for related research and auxiliary diagnosis of neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is the electrophoresis detection diagram of antibody recognition of neuronal exosomes. DETAILED DESCRIPTION
[0033] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvement by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0034] In the context of the present invention, the term "antibody" is used in the broadest sense in the present invention, and explicitly covers monoclonal antibodies, polyclonal antibodies, humanized antibodies, chimeric antibodies, and multispecific antibodies (e.g., bivalent antibodies) formed from at least two complete antibodies, as long as they exhibit the desired biological activity. In the present invention, the antibody sequences obtained by modification also belong to the protection scope of the present invention. The term "modification" refers to any form of modification of the amino acid sequence, such as substitution, deletion, insertion and / or addition of amino acids. The term "substitution" refers to the replacement of one or more amino acids in the original amino acid sequence with different amino acids. The term "deletion" refers to the reduction of one or more amino acids in the original amino acid sequence. The term "insertion" or "addition" refers to the change in the amino acid sequence resulting in the addition of one or more amino acids compared to the original amino acid sequence. In the present invention, the modification preferably occurs in an area outside the variable region, such as the constant region or framework region of the antibody, and the modified antibody still retains the desired functional properties of the antibody or antigen-binding fragment thereof of the present invention, or has improved antigen-binding properties.
[0035] In the present invention, the term "antigen binding fragment" includes a part of a complete antibody, and generally refers to one or more fragments of an antibody that play a specific antigen binding function. The antigen binding function of an antibody can be achieved by a full-length fragment of the antibody. In the present invention, the antigen binding fragment comprises its light chain variable region and heavy chain variable region, and in some embodiments comprises LCDR1-3 of its light chain variable region and HCDR1-3 of its heavy chain variable region, and in a specific embodiment comprises the amino acid sequence shown in SEQ ID NO:5-7 and SEQ ID NO:8-10. The term "binding" means that the binding effect is selective for the antigen and can be distinguished from undesirable or non-specific interactions. The ability of an antigen binding site to bind to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA) or conventional binding assays known in the art.
[0036] In the present invention, the terms "heavy chain variable region" and "light chain variable region" refer to the structure of an antibody from N-terminus to C-terminus, where each antibody heavy chain has a heavy chain variable region, also known as a heavy chain variable domain, followed by three heavy chain constant domains CH1, CH2 and CH3; similarly, from N-terminus to C-terminus, each antibody light chain has a light chain variable region, also known as a light chain variable domain, followed by a light chain constant domain. The heavy chain variable region and the light chain variable region can be further divided into hypervariable regions (i.e., CDRs) and relatively conservative regions (i.e., framework regions FRs) interposed between the hypervariable regions.
[0037] In the present invention, the term "CDR" refers to the "hypervariable region" or "complementarity determining region" of an antibody. Both the heavy chain variable region and the light chain variable region have three CDRs, which together constitute the antigen binding site of the antibody and can form precise complementarity with the antigenic determinant in terms of spatial structure. Examples of other antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from different antibody fragments. The position of CDR in the variable region has different notations according to different numbering systems, and the numbering schemes include IMGT, Chothia, Kabat, etc. The IMGT numbering scheme is based on the amino acid sequence alignment of germline V genes; the Chothia numbering scheme is based on crystal structure; and the Kabat numbering scheme defines the variability parameter as the number of different amino acids at a given position divided by the frequency of the most amino acids at that position. According to different CDR determination schemes, the residues in the CDR are as described in Table 1. In the present invention, the sequences of LCDR1-3 and HCDR1-3 are shown in SEQ ID NO: 5-7, 8-10, and the numbering scheme is IMGT.
[0038] Table 1. CDR residues with different numbering schemes
[0039]
[0040] Note 1: If both H35A and H35B do not exist, HCDR1 ends at position 32; if only H35A exists, HCDR1 ends at position 33; if both H35A and H35B exist, HCDR1 ends at position 34.
[0041] In the present invention, the term "nucleic acid molecule" refers to any polymer form having any length and consisting of ribonucleotides or deoxyribonucleotides. Generally, a nucleic acid molecule is a coding sequence, as used herein, which refers to a DNA sequence that is transcribed and translated into a polypeptide in a host cell when placed under the control of an appropriate regulatory sequence. The boundaries of the coding sequence are determined by the start codon at the 5' (amino) end and the translation stop codon at the 3' (carboxyl) end. The coding sequence may include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even recombinant DNA sequences. The transcription termination sequence will generally be located at 3' of the coding sequence. In the present invention, the nucleic acid molecule comprises a base sequence capable of encoding the antibody and antigen-binding fragment thereof described in the first aspect of the present invention, in some embodiments, comprising LCDR1-3 of the light chain variable region shown in SEQ ID NO: 3 and HCDR1-3 of the heavy chain variable region shown in SEQ ID NO: 4, and in a specific embodiment, comprising the base sequences shown in SEQ ID NO: 11-13 and SEQ ID NO: 14-16.
[0042] In the present invention, a vector comprising the nucleic acid molecule of the present invention is provided. The term "vector" refers to an artificial construct that can deliver and preferably express one or more target genes or sequences in a host cell. The vector of the present invention can be a plasmid vector, a viral vector, etc. In some embodiments, the vector refers to a linear or circular nucleic acid molecule that comprises a nucleic acid of the present invention that is operably connected to other segments of autonomous replication provided in a recombinant host cell, or an expression cassette according to a nucleic acid molecule. "Operably connected" means that the nucleic acid sequence of interest is connected to a regulatory sequence (e.g., in an in vitro transcription / translation system or when the vector is introduced into a host cell) in a manner that allows the expression of the nucleotide sequence.
[0043] In the present invention, the term "recombinant host cell" refers to the introduction of the vector of the present invention into a host cell, so that the recombinant host cell can transcribe the target nucleic acid sequence and / or translate the target protein. In the present invention, the recombinant host cell can express the antibody or antigen-binding fragment thereof described in the first aspect of the present invention through such genetic engineering technology, thereby achieving the method described in the fourth aspect of the present invention.
[0044] The fourth aspect of the present invention provides a method for preparing the antibody or antigen-binding fragment thereof according to the first aspect of the present invention, wherein the method comprises artificial synthesis or preparation by genetic engineering technology.
[0045] In certain embodiments, the antibodies of the present invention are obtained by artificial synthesis. Methods for artificially synthesizing antibodies are known in the art, for example, antibodies of the present invention or antigen-binding fragments thereof are obtained by direct amino acid synthesis. In certain embodiments, the antibodies of the present invention are obtained by genetic engineering expression. Genetic engineering expression systems include prokaryotic cell expression systems, eukaryotic cell expression systems, and cell-free expression systems. Examples of prokaryotic cell expression systems include Escherichia coli expression systems. Eukaryotic cell expression systems include zymogen expression systems, insect cell expression systems, and mammalian cell expression systems.
[0046] In the present invention, the term "antibody derivative" refers to a derivative comprising the antibody of the present invention and a detectable marker bound to the antibody, which can exhibit the desired biological activity and can be detected by the detectable marker attached thereto. The detectable marker includes at least one of a radioactive isotope, a metal nanomaterial, fluorescein, biotin, avidin, a biotin / avidin complex, a biotin / avidin protein complex, a chromophore, an electron-dense substance, and an enzyme.
[0047] In the present invention, the term "exosome" refers to a class of extracellular vesicles of endocytic origin, which carry mRNA, non-coding RNA, proteins, lipids, DNA and other bioactive substances of the source cells and play a role in many physiological processes. In the brain, exosomes are involved in processes such as synaptic plasticity, neuronal stress response, intercellular communication and neurogenesis. Exosomes can cross the blood-cerebrospinal fluid barrier, and the content varies with their secretion and receptor cells, and can be used as biomarkers for neurological dysfunction. Intercellular communication in the central nervous system plays an important role in the growth, development and maintenance of homeostasis of the brain. Studying neuronal exosomes can provide information for disease diagnosis and therapeutic intervention.
[0048] In the present invention, the term "neurodegenerative disease" refers to a disease caused by the loss of neurons and / or their myelin sheaths, which worsens over time and causes functional impairment. Neurodegeneration or neurodegeneration refers to the gradual loss of neuronal structure and function, including neuronal death and glial cell balance, which can lead to cognitive disorders such as dementia. Neurodegenerative diseases include Alzheimer's disease, Parkinson's syndrome, Huntington's disease, multiple sclerosis, primary lateral sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, etc. The most common pathological signs of neurodegenerative diseases are plaques and tangles in the brain. Plaques are composed of α, β-synuclein amyloid β protein and others, while tangles are mainly composed of hyperphosphorylated tau protein. Studies have shown that a variety of proteins related to neurodegenerative diseases are related to the regulation of neuronal migration, most of which are neuronal transporters (TNTP) present in neuronal exosomes. Viral TNTP, including tau protein and β-synuclein, has been detected in isolated exosomes and postsynaptic neurons. The antibodies provided by the present invention can specifically capture neuron-derived exosomes, and the exosomes captured by the antibodies can be used as samples for diagnosing neurodegenerative diseases.
[0049] In the present invention, the term "ELISA" or "enzyme-linked immunosorbent assay" refers to a method for quantitatively or semi-quantitatively determining the protein concentration of a sample (e.g., hybridoma cells) in a multi-well plate format (usually 96 wells per plate). In brief, proteins in solution are adsorbed onto an ELISA plate. Antibodies specific for the protein of interest can be used to probe the plate. Background is minimized by optimizing blocking and washing methods, and specificity is ensured by the presence of positive and negative controls. Detection methods are typically based on colorimetry or chemiluminescence.
[0050] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Simple improvements to the present invention made according to the essence of the present invention all belong to the scope of protection claimed in the present invention. It should be noted that the experimental methods in the following examples, unless otherwise specified, are conventional methods, and the materials and reagents used in the following examples, unless otherwise specified, are all obtained from commercial sources.
[0051] Example 1 Preparation of L1CAM Antibody
[0052] 1. Immunogen processing: The immunogen is recombinant L1CAM protein. The protein purity and molecular weight were identified by SDS-PAGE and processed by ImmunoPlus technology to enhance immunogenicity.
[0053] 2. Animal immunization: BALB / c mice were selected and immunized by conventional methods. After three immunizations, the titer of antiserum was tested by indirect ELISA method, and mice with high titer were selected for subsequent experiments. Western test was used to test the recognition of antiserum to recombinant antigen.
[0054] 3. Preparation of spleen cells: Kill the mouse by cervical stenosis, remove the spleen under sterile conditions, and place it in a sterilized 90-100 mesh stainless steel net. Use a syringe to inject 3 ml of serum-free culture medium into the spleen, repeatedly aspirate several times to obtain cells, and then make a cell suspension. Inject the cell suspension into a 50 ml centrifuge tube, add 10-20 ml of culture medium, gently blow several times, and let it stand at room temperature for 5 minutes. Centrifuge (800-1000 rpm), count, and set aside.
[0055] 4. Cell fusion: Mix mouse myeloma cells and mouse spleen cells in a ratio of 1:5, centrifuge and discard the supernatant, and absorb the excess supernatant with sterile filter paper. Add 1 ml of 40% PEG solution dropwise to the cell mass within 60 seconds, while gently rotating the centrifuge tube. In the rotating centrifuge tube, add 1 ml of serum-free culture medium dropwise within 60 seconds. Then slowly add 20 ml of serum-free culture medium within 5 minutes. Centrifuge (800 rpm, 8 minutes), remove the supernatant, suspend with 10 ml of complete culture medium, and mix gently. Add the cell suspension to a 96-well plate, 50 microliters per well. After culturing in a 37°C CO2 incubator for 24 hours, replace it with HAT selective culture medium.
[0056] 5. Post-fusion cell culture: 7-10 days after fusion, replace the medium with half of the HAT medium, and then replace the medium every 2-3 days. After 2-3 weeks, hybrid cell colonies will appear. When the colonies proliferate and grow to 1 / 3 of the well, use the indirect ELISA method to test the affinity of the monoclonal antibodies in the culture supernatant of mouse hybridoma cells.
[0057] 6. Sequencing: The monoclonal antibodies in the culture supernatant of mouse hybridoma cells were sequenced. The amino acid and base sequences of the L1CAM antibody and its antigen-binding fragment provided by the present invention are shown in Table 2:
[0058] Table 2. Amino acid / base sequence corresponding to SEQ ID
[0059]
[0060]
[0061] Example 2 ELISA method to detect antibody affinity
[0062] The indirect ELISA method was used to detect the affinity of monoclonal antibodies in the culture supernatant of mouse hybridoma cells. The specific steps are as follows:
[0063] 1) The recombinant protein was used as an antigen to coat the ELISA plate. The coating antigen concentration was 1 μg / ml, 100 μl / well. The coating buffer was PBS (pH = 7.4).
[0064] 2) Incubate at 4°C overnight and wash with PBS three times the next day for 5 minutes each time.
[0065] 3) Add 200 μl 1% BSA to each well for blocking and incubate at 37°C for 2 hours.
[0066] 4) Discard BSA and add cell culture supernatant containing monoclonal antibody, 100 μl per well. Use blank culture supernatant as negative control.
[0067] 5) Incubate in a 37℃ incubator for 2 hours. Discard the primary antibody, wash 5 times with detergent, add 2554 Goat Anti-Mouse IgG, and incubate in a 37℃ incubator for 1 hour.
[0068] 6) After adding the substrate for color development, the absorbance was measured with an enzyme marker. The results are shown in Table 3. The absorbance of the antibody is >2, which is much larger than the negative control value of 0.076, indicating that the antibody has a good affinity for the recombinant protein antigen.
[0069] Table 3. Antibody recognition of recombinant proteins
[0070]
[0071] Example 3 Electrophoresis to detect binding activity
[0072] Two neuronal exosomes were used as antigens and electrophoresis was performed using monoclonal antibodies in the culture supernatant of mouse hybridoma cells. Figure 1As shown, a strong positive band appeared at around 50 kD, indicating that the antibody has a strong binding affinity to neuronal exosomes.
[0073] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. An antibody or antigen-binding fragment thereof against human L1CAM protein, characterized in that: The antibody or antigen-binding fragment thereof comprises LCDR1-LCDR3 of the light chain variable region as shown in SEQ ID NO: 1; and The antibody or antigen-binding fragment thereof comprises HCDR1-HCDR3 of the heavy chain variable region as shown in SEQ ID NO: 2; The amino acid sequence of LCDR1 in the light chain variable region is QSVDYDGDGY, the amino acid sequence of LCDR2 in the light chain variable region is GAS, and the amino acid sequence of LCDR3 in the light chain variable region is QHGSDDPFT; The amino acid sequence of HCDR1 of the heavy chain variable region is GYTITNYG, the amino acid sequence of HCDR2 of the heavy chain variable region is INTYTGEP, and the amino acid sequence of HCDR3 of the heavy chain variable region is ARPITTVVEGRFAY.
2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibodies include monoclonal antibodies, polyclonal antibodies, humanized antibodies, chimeric antibodies or bivalent antibodies.
3. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the antibody or antigen-binding fragment thereof according to any one of claims 1-2.
4. The nucleic acid molecule according to claim 3, characterized in that The nucleic acid molecule comprises a base sequence encoding LCDR1-LCDR3 in the light chain variable region base sequence as shown in SEQ ID NO: 3; and The nucleic acid molecule comprises a base sequence encoding HCDR1-HCDR3 in the heavy chain variable region base sequence as shown in SEQ ID NO:4; Wherein, the base sequence encoding LCDR1 is CAAAGTGTTGATTATGATGGTGACGGTTAT, The base sequence encoding LCDR2 is GGTGCATCC, The base sequence encoding LCDR3 is CAGCACGGTAGTGATGATCCATTCACG; The base sequence encoding HCDR1 is GGATATACGATCACAAACTATGGA, The base sequence encoding HCDR2 is ATAAACACCTACACTGGAGAGCCA, The base sequence encoding HCDR3 is GCAAGACCTATTACTACGGTAGTAGAAGGCAGGTTTGCTTAC.
5. A carrier, characterized in that The vector comprises the nucleic acid molecule according to any one of claims 3-4.
6. A recombinant host cell, characterized in that The recombinant host cell comprises the nucleic acid molecule according to any one of claims 3 to 4, or the vector according to claim 5.
7. An antibody derivative, comprising the antibody or antigenic fragment thereof according to any one of claims 1 to 2 and a detectable marker coupled thereto; The detectable label comprises at least one of a radioisotope, a metal nanomaterial, a fluorescein, a biotin, avidin, a biotin / avidin protein complex, a biotin / avidin protein complex, a chromophore, an electron-dense substance, and an enzyme.
8. A method for preparing the antibody or antigenic fragment thereof according to any one of claims 1 to 2, said method comprising artificial synthesis or preparation by genetic engineering technology; The preparation by genetic engineering technology refers to culturing the recombinant host cell according to claim 6 under conditions suitable for expressing the antibody or antigen-binding fragment thereof.
9. A method for detecting human L1CAM protein, detecting or capturing neuronal exosomes for non-diagnostic purposes, the method comprising using the antibody or antigenic fragment thereof according to claim 1 or 2 and / or the antibody derivative according to claim 7 to detect human L1CAM protein, and detecting or capturing neuronal exosomes.
10. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 2, the nucleic acid molecule according to any one of claims 3 to 4, the vector according to claim 5, the recombinant host cell according to claim 6 and / or the antibody derivative according to claim 7 in preparing a product, characterized in that: The application includes any of the following: 1) Application in the preparation of products for detecting human L1CAM protein; 2) Application in the preparation of products for detecting or capturing neuronal exosomes; 3) Application in the preparation of products for diagnosing neurodegenerative diseases; The neurodegenerative diseases include Alzheimer's disease, Parkinson's syndrome, Huntington's disease, multiple sclerosis, primary lateral sclerosis, amyotrophic lateral sclerosis, and myasthenia gravis.
